Vcanbio Cell & Gene Engineering Corp., Ltd
600645.SS · SHH
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 1.55B | 1.04B | 156.01M | 112.99M | 0.24 |
| 2023 FY | 1.59B | 1.08B | 131.12M | 106.45M | 0.23 |
| 2024 FY | 1.59B | 1.09B | 135.79M | 100.35M | 0.22 |
| 2025 FY | 1.45B | 1.02B | 177.65M | 113.83M | 0.25 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 5.28B | 1.63B | 1.39B | 129.58M | 3.56B |
| 2023 FY | 5.41B | 1.61B | 1.58B | 115.88M | 3.68B |
| 2024 FY | 5.25B | 1.59B | 1.52B | 68.40M | 3.60B |
| 2025 FY | 5.29B | 1.54B | 1.01B | 68.80M | 3.71B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 261.89M | -99.19M | 162.70M | -1.27M | 191.10M |
| 2023 FY | 299.02M | -88.61M | 210.40M | -917.35K | 200.02M |
| 2024 FY | 285.19M | -67.32M | 217.87M | -591.24K | -56.28M |
| 2025 FY | 313.63M | -49.56M | 264.07M | — | -517.56M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 7.96B | 6.70B | — | — | — |
| 2023 FY | 9.38B | 7.92B | — | — | — |
| 2024 FY | 8.80B | 7.35B | — | — | — |
| 2025 FY | 11.47B | 10.54B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 365.58M | 245.83M | 38.95M | 29.74M | 0.06 |
| 2025 Q3 | 376.09M | 264.06M | 57.60M | 50.14M | 0.11 |
| 2025 Q4 | 362.49M | 259.97M | 34.41M | 5.92M | 0.01 |
| 2026 Q1 | 317.34M | 220.77M | 37.43M | 24.24M | 0.05 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 5.25B | 1.55B | 988.83M | 54.21M | 3.65B |
| 2025 Q3 | 5.32B | 1.56B | 1.12B | 72.65M | 3.71B |
| 2025 Q4 | 5.29B | 1.54B | 1.01B | 47.28M | 3.71B |
| 2026 Q1 | 5.27B | 1.50B | 1.58B | 74.32M | 3.72B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 76.64M | -12.93M | 63.70M | — | -562.58M |
| 2025 Q3 | 103.70M | -13.28M | 90.42M | — | 131.45M |
| 2025 Q4 | 90.77M | -12.43M | 78.34M | — | -112.85M |
| 2026 Q1 | 28.15M | -8.19M | 19.95M | — | 576.82M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 10.84B | 9.90B | — | — | — |
| 2025 Q3 | 11.27B | 10.22B | — | — | — |
| 2025 Q4 | 11.85B | 10.89B | — | — | — |
| 2026 Q1 | 14.98B | 13.47B | — | — | — |